LDLR and familial hyperaldosteronism: This genetic correction restored LDLR-mediated endocytosis in FH-HLCs and is a proof-of-principle that CRISPR-mediated genetic modification can be successfully used to normalize HoFH cholesterol metabolism deficiency at the cellular level.